Sociedad Americana de Hirudoterapia

Identifying and Prioritising BSACI Service Standards for Paediatric Allergy in the United Kingdom

Research article published in Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2025)

Última actualización: 18 de junio de 2026Revisado por: ASH Editorial Board
Artículo de investigación — revisión de evidenciaReferencia del artículo
Evidence: Research reportEnsayos clínicosSeguridad y control de infeccionesTurner PJ et al. · Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2025

Abstract

BACKGROUND: Demand for paediatric allergy services has risen significantly over the past 20 years. National health datasets suggest almost 40% of children have an allergy diagnosis. Existing service standards from the Royal College of Paediatrics and Child Health (RCPCH) have focused on specific disease care pathways and the interface between primary and secondary care services. Given strategic changes to NHS children and young people's services, we undertook a collaborative project between RCPCH and the British Society of Allergy and Clinical Immunology (BSACI) to define service priorities for Paediatric Allergy Care accreditation in the UK. METHODS: A BSACI working group developed 29 potential service standards. A consultation was then undertaken amongst BSACI members to identify indicative priorities. Potential standards were then prioritised using methodology adapted from the James Lind Alliance, by 24 stakeholders representing patients/patient groups (9), commissioners (2) and healthcare professionals (13). RESULTS: Seventeen strategic priorities were identified, under the following 6 themes: service delivery, prevention, diagnostics, management, communication, maintaining standards/education. These included: setting a minimum staffing mix for multidisciplinary teams providing paediatric allergy care (medical specialist(s), specialist nurse, dietitian, health psychologist); prompt recognition and management of complex, multisystem allergic disease; working within a regional network to ensure access to specialist paediatric allergy services; use of integrated care pathways and supporting primary care accordingly; supporting early access to interventions proven to reduce the risk of atopic disease (with consideration to potential barriers to access, including language, cultural, socioeconomic factors and other communication barriers); offering a referral pathway for disease-modifying treatment where appropriate and effective transitioning to adult care. CONCLUSIONS: These priorities form a basis for the delivery of high-quality care to children and young people affected by allergic disease.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsHumansUnited KingdomChildHypersensitivityAllergy and ImmunologyPediatricsDelivery of Health Care

Resumen

Demand for paediatric allergy services has risen significantly over the past 20years.

Por qué esto importa para la hirudoterapia

Este artículo detalla un proyecto colaborativo entre importantes organizaciones sanitarias para identificar y priorizar estándares de servicio para la atención alergológica pediátrica en el Reino Unido, centrado en temas como la prestación de servicios, la prevención, el diagnóstico y el manejo. No presenta ningún vínculo defendible ni relevancia con la American Society of Hirudotherapy, la biología de las sanguijuelas ni el secretoma de las sanguijuelas. El resumen se enfoca por completo en marcos de administración sanitaria y vías clínicas para enfermedades alérgicas en niños, sin mencionar la hirudoterapia ni ninguna intervención relacionada. Por lo tanto, este artículo no aporta ningún conocimiento aplicable, ninguna visión clínica ni ninguna utilidad de fondo para el dominio de investigación de la ASH.

Citación

Identifying and Prioritising BSACI Service Standards for Paediatric Allergy in the United Kingdom

Turner PJ et al. · Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2025

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.